H.C. Wainwright raised the firm’s price target on Dogwood (DWTX) to $12 from $10 and keeps a Buy rating on the shares after the company announced a new licensing agreement with Serpin Pharma.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma
- Dogwood secures royalty free license to develop, commercialize SP16
- Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning
- Dogwood Therapeutics Reports Q2 2025 Financial Results
- Dogwood reports Q2 EPS ($1.99) vs ($1.15) last year